Diabetes drug metformin shows promise against rectal cancer

NCT ID NCT02437656

Completed Disease control Sponsor: Centre Oscar Lambret Source: ClinicalTrials.gov ↗

First seen Mar 18, 2026 · Last updated May 23, 2026 · Updated 11 times

Summary

This study looked at whether adding the diabetes drug metformin to standard chemo-radiation helps shrink rectal tumors before surgery. 60 adults with locally advanced rectal cancer took part. The main goal was to see if more patients had no cancer cells left in the removed tumor. Metformin is already known to be safe for diabetes and may slow cancer growth.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Centre Galilée - Hôpital Privé La Louvière

Lille, 59045, France
Centre Gray

Maubeuge, 59600, France
Centre Hospitalier

Lens, 62300, France
Centre Joliot-Curie

Saint-Martin-Boulogne, 62200, France
Centre Léonard de Vinci - SARL du pont Saint Vaast

Douai, 59500, France
Centre Marie Curie

Arras, 62000, France
Centre Oscar Lambret

Lille, 59020, France
Centre Pierre Curie

Beuvry, 62880, France
Clinique des Dentellières

Valenciennes, 59300, France
Clinique du Bois - Centre Bourgogne

Lille, 59000, France
Institut André Dutreix

Dunkirk, 59240, France

Conditions

Explore the condition pages connected to this study.

RECTAL CANCER